Chinese 3SBio goes private; Sanofi's Gaucher disease drug moves forward;

 @FierceBiotech: Still trending: The 25 most influential people in biopharma today - 2013. Special Report | Follow @FierceBiotech

@JohnCFierce: Mega-mergers are back (expect 1-2 big deals in biopharma this year). News | Follow @JohnCFierce

@RyanMFierce: Japan takes lead in trialing a human stem cell therapy. Story | Follow @RyanMFierce

> Chinese biotech company 3SBio has struck a $340 million deal to be taken private by the Chinese CITIC Private Equity. Story

> Amicus Therapeutics ($FOLD) announced more results from its ongoing PhIII trial of its investigational oral migalastat HCl monotherapy in patients with Fabry disease. Release

> Modulation Therapeutics has received an undisclosed amount of seed funding from the Institute for the Commercialization of Public Research to help further develop a therapy for myeloma, an incurable blood cancer. Release

> Janssen has partnered with the U.K.'s National Health Service for a new program aimed at advancing dementia care. Story

> Sanofi ($SNY) says its experimental pill for Gaucher disease met its main targets in two late-stage studies, moving it closer to regulatory approval. Story

Pharma News

@FiercePharma: Shire's Vyvanse tops $1B as more generics challenge Adderall. Report | Follow @FiercePharma

@EricPFierce: Mylan currently the focus of a hot rumor for picking up the sterile injectables unit of India's Strides Arcolab. News | Follow @EricPFierce

@AlisonBFierce: A promising new vaccine--administered as a nasal spray--is shrinking head and neck tumors. More | Follow @AlisonBFierce

> Seroquel XR patent upheld, protecting AZ blockbuster. News

> Premium pricing for Novo's Tresiba in EU, a tiny bit of good news. Story

> Congressmen want FDA to act now on restricting painkillers. Item

Medical Device News

 @FierceMedDev: Cohera snags $17M to support TissuGlu. News | Follow @FierceMedDev

 @MarkHFierce: Weight loss devices never go out of style. BAROnova secured a $27.3M Series C for its contribution to the space. More | Follow @MarkHFierce

 @DamianFierce: St. Jude is studying whether renal denervation can treat heart attack and stroke in addition to hypertension. Press release | Follow @DamianFierce

> Acquisitions help boost Alere's 2012 Q4 revenue. Item

> J&J braces international market for more metal hip problems. Article

> Second Sight scores victory with FDA nod for retinal prosthesis. News

And Finally... Swedish fish come out of their shells--so to speak--with anti-anxiety drug. Story

Suggested Articles

Myovant’s uterine fibroid drug reduced blood loss in nearly three-quarters of patients, trouncing placebo in the second of two phase 3 studies.

The cystic fibrosis biotech unveiled Belous’ appointment alongside news of the promotion of Geoff Gilmartin to the CMO position.

The series C round is the latest in a series of boosts for Frequency’s attempts to tackle hearing loss through the activation of progenitor cells.